
Hims & Hers Health Stock Slides Friday: What's Going On?
Track HIMS's AI-powered predictions, market trends, and investment insights.
StockTwits Mentions
531
HIMS has been mentioned an estimated 531 times on StockTwits over the last 24 hours.
Upgrade to see the full Evidence Stack
What Changed, Why Now, and Risk Flags — available on the Investor plan and above
Get StartedThe negative EPS of -0.09 and an effectively meaningless, deeply negative PE ratio of -291 indicate that hims is still unprofitable on a GAAP earnings basis. While the market may be pricing in growth and potential operating leverage, current reported profitability remains weak. Without evidence of a clear and near-term path to sustained positive earnings, the financial profile skews more risky than not.
At $26.19, hims is trading about 4.6% higher over the last month, indicating some short-term positive momentum. However, the stock is well below its 200-day moving average of $34.14, which is a classic sign of a longer-term downtrend or overhead resistance. The combination suggests a weak intermediate technical setup despite a modest recent bounce.
Alternative data for hims is mixed but generally stable to modestly positive. Web traffic at an estimated 172,083 visitors per month and 63 job openings (down 8.7% month over month) suggest a business that is active but perhaps moderating its growth or hiring pace. Social media followings across Instagram, Facebook, and LinkedIn are growing slowly, indicating steady brand awareness but not explosive consumer traction.
Overall, hims presents a mixed picture: the company remains unprofitable with a very high implied valuation multiple, and the stock trades below its 200-day moving average despite a recent price uptick. Alternative data show steady but not explosive engagement and a slight pullback in hiring, consistent with a company balancing growth and cost discipline. Taken together, the signals lean toward a neutral stance, with meaningful execution risk but also embedded growth expectations already reflected in the stock.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
You don't hold HIMS in your mock portfolio yet.

Hims & Hers Health Stock Slides Friday: What's Going On?



Hims & Hers Names Dr. Anant Vinjamoori as Chief Medical Officer of Hims
HIMS StockTwits activity is running at a notably high clip, with 2,826 mentions recorded over the past seven days. That level of social engagement places Hims & Hers Health firmly on the radar of active retail traders, suggesting the stock is generating consistent discussion rather than a single-day spike. At a current price of $26.15 — up 3.0% on the day — the conversation appears to be tracking positive short-term price momentum. With over 20.6 million shares traded in a single session, the StockTwits chatter is being backed by real market participation, not just idle commentary.
Context matters when interpreting StockTwits mention volume. HIMS carries a TrendEdge AI Score of 5 out of 10 — a neutral reading — which suggests the social enthusiasm is not yet translating into a broadly bullish technical or fundamental signal. The 3.0% single-day price gain and heavy volume of 20.6 million shares indicate traders are actively positioning, but the moderate AI score warrants caution. Social momentum and price momentum are aligning short-term, yet the $5.8 billion market cap stock still has meaningful ground to cover before sentiment converts into sustained institutional conviction.
TrendEdge aggregates HIMS StockTwits data alongside Reddit mentions — currently 14 over the past seven days — to distinguish between broad retail enthusiasm and concentrated community-driven activity. By combining social mention volume with proprietary AI scoring and alternative data signals, TrendEdge gives traders a multi-layered view of sentiment. This approach helps identify whether a spike in StockTwits activity reflects genuine momentum or short-term noise, giving you a sharper edge than any single data source alone.
Unlock comprehensive alternative data signals to make better investment decisions
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
Web Traffic
203,140
Twitter Followers
31,845
Instagram Followers
256,289
LinkedIn Followers
229,047
Job Postings
67
LinkedIn Employees
2,048
News Mentions
1
Key Metrics